Bull & Bear

Bull and Bear

Verdict: Watchlist — the mix-shift facts are real and the valuation is genuinely cheap, but the single line item that decides whether this is a turnaround or a treadmill (S&M as % of revenue) failed to bend in the most favorable year of the cycle, and the founder-affiliated convertible's dilution terms are still undisclosed.

The bull and the bear are not arguing about different facts; they are arguing about which line of the FY2025 income statement is the inflection. Bull points at the headline (op loss ¥-825M → ¥-186M, first profitable Q, skincare 53% of revenue and accelerating). Bear points at the mechanism (S&M moved 60 bps in a +26.7% revenue year; the rest of the deleverage was the non-recurrence of the ¥403M Eve Lom goodwill hit plus 600 bps of G&A cuts). One H1 FY2026 print — S&M ratio and trailing OCF — resolves the debate. Until that print and the convertible's conversion price are public, the asymmetry is not yet readable. This is a deferred decision, not a no-edge debate.

Bull Case

Bull scenario value range: ~¥49 per ADS (≈2.5× current ¥19.6). Method: FY2026 revenue ¥5.1B (mid-point of company guide, +19% YoY) × 0.75× EV/Revenue (still a 65% discount to the 2.1× peer median) + ¥850M net cash, divided by ~93M ADS. Cross-check at ¥5.1B × 5% operating margin × 18× P/E lands at ~¥4.6B equity. Timeline: 12–18 months. Disconfirming signal: S&M as % of revenue above 67% for any single quarter in FY2026, or skincare YoY growth decelerating below 25% before S&M bends — either would suggest the gross-margin moat does not reach the operating line.

Bear Case

Bear scenario value range: ~¥10 per ADS (~50% downside from ¥19.64). Method: EV/Sales compression to 0.12× on FY26 revenue ¥4.4B yields ¥530M EV; add ~¥600M residual net cash to get ~¥1.13B market cap; divide by ~115M ADS post-conversion of the founder-affiliated convertible at a ¥17–19 strike → ~¥9.8/ADS. Cross-checked against a 35% discount to forward tangible book → ¥11.0/ADS. Timeline: 12–18 months. Cover signal: Quarterly S&M ratio below 60% in any single quarter AND operating cash flow positive on a trailing-four-quarter basis. Either alone is rebuttable; both together invalidate the marketing-treadmill core of the short.

The Real Debate

Verdict

Watchlist. The bear carries more weight today because the single mechanism that turns Yatsen's 78% gross margin into operating profit — the S&M ratio — moved only 60 bps in the most operating-leverage-favorable year possible, while the headline P&L improvement is mechanically traceable to the non-recurrence of a one-time goodwill impairment. The decisive tension is the first one in the ledger: what actually drove the FY2025 operating loss compression. The bull could still be right because the skincare mix shift is genuinely accelerating (+63.5% FY25, +51.9% Q4), gross margin is the second-highest in the listed peer set, the valuation is structurally cheap (0.20× EV/Sales vs 2.1× peer median, equity below tangible book), and management has compounded share count reductions below tangible book. The verdict flips to Lean Long, Wait For Confirmation when one H1 FY2026 print shows S&M intensity below 62% and trailing-four-quarter operating cash flow positive, AND the Trustar/founder convertible's conversion price is disclosed at a level meaningfully above spot. Until both prints, the decisive variable lives outside the available evidence and the cheap valuation does not yet pay for the marketing-treadmill risk or the unknown dilution overhang.